Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Colorectal Cancer | Primary research

MicroRNA-196b-5p promotes malignant progression of colorectal cancer by targeting ING5

Authors: He Xin, Chuanzhuo Wang, Yuan Chi, Zhaoyu Liu

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

miR-196b-5p expression is deregulated in many malignant tumors. Although miR-196b-5p has been implicated in the malignant transformation of colorectal cancer, its role in this specific type of cancer has not been fully explored. Thus, the present study was aimed to examine the cellular function of miR-196b-5p and its role in malignant biological behavior in colorectal cancer.

Methods

miR-196b-5p expression was measured in colorectal cancer tissues and cell lines using quantitative real-time PCR. Cell counting kit-8 (CCK-8) assay and Transwell assay were used to detect proliferation, migration, and invasion in cell lines, whereas flow cytometry was applied to study apoptosis. Western blot analysis was performed to measure the protein levels. Dual luciferase reporter assay was used to investigate the interaction between miR-196b-5p and ING5. Tumor formation was evaluated in mice.

Results

MiR-196b-5p was abundantly expressed in colorectal cancer tissues and cell lines, whereas ING5 was expressed at low levels. MiR-196b-5p was successfully overexpressed or knocked down in colorectal cancer cells. We found that miR-196b-5p overexpression significantly accelerated the proliferation, cell cycle, migration and invasion, while inhibited cell apoptosis in colorectal cancer cells. However, miR-196b-5p inhibitor showed the opposite effects. Moreover, ING5 overexpression or knockdown was successfully performed in colorectal cancer cells. ING5 overexpression suppressed proliferation, migration, invasion, the phosphorylation of PI3K, Akt as well as MEK, and promoted cell apoptosis, which could be reversed by ING5 knockdown. Additionally, ING5 was identified as a target of miR-196b-5p through bioinformatics analysis and a luciferase activity assay. Furthermore, ING5 knockdown could attenuate the decrease in proliferation, migration, invasion, and the protein levels of p-PI3K, p-Akt, and p-MEK, which were induced by miRNA-196b-5p inhibitor. Besides, miR-196b-5p knockdown inhibited tumor growth, whereas ING5 knockdown elevated it in vivo.

Conclusions

In conclusion, miR-196b-5p promotes cell proliferation, migration, invasion, and inhibits apoptosis in colorectal cancer by targeting ING5.
Appendix
Available only for authorised users
Literature
1.
Hasegawa H, Kitagawa D, Shibahara K, Funahashi S, Kitamura M. Study of the treatment for colorectal cancer(CRC)in elderly people aged 80 years or older. Gan to kagaku ryoho Cancer Chemother. 2019;46(4):742–4.
2.
Tangka FKL, Subramanian S, Hoover S, Cole-Beebe M, DeGroff A, Joseph D, Chattopadhyay S. Expenditures on screening promotion activities in CDC’s colorectal cancer control program, 2009–2014. Prev Chronic Dis. 2019;16:E72.PubMedPubMedCentralCrossRef
3.
Lok SW, Wong HL, Kosmider S, Field K, Tie J, Desai J, Bae S, Tacey M, Skinner I, Jones I, et al. Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice. Asia Pac J Clin Oncol. 2014;10(4):361–7.PubMedCrossRef
4.
Athanasakis E, Xenaki S, Venianaki M, Chalkiadakis G, Chrysos E. Newly recognized extratumoral features of colorectal cancer challenge the current tumor-node-metastasis staging system. Ann Gastroenterol. 2018;31(5):525–34.PubMedPubMedCentral
5.
Ogura T, Muta Y, Ito T, Chika N, Hatano S, Amano K, Ishiguro T, Fukuchi M, Kumagai Y, Ishibashi K, et al. Prognostic impact of tumor location of colorectal cancer in patients with resected liver metastasis. Gan to kagaku ryoho Cancer Chemother. 2017;44(12):1461–3.
6.
Fan C, Lin Y, Mao Y, Huang Z, Liu AY, Ma H, Yu D, Maitikabili A, Xiao H, Zhang C, et al. MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2. Oncotarget. 2016;7(16):21825–39.PubMedPubMedCentralCrossRef
7.
Lan YT, Yang SH, Chang SC, Liang WY, Li AF, Wang HS, Jiang JK, Chen WS, Lin TC, Lin JK. Analysis of the seventh edition of American Joint Committee on colon cancer staging. Int J Colorect Dis. 2012;27(5):657–63.CrossRef
8.
Chang GJ, Kaiser AM, Mills S, Rafferty JF, Buie WD. Practice parameters for the management of colon cancer. Dis Colon Rectum. 2012;55(8):831–43.PubMedCrossRef
9.
Chen Y, Zhang B, Jin Y, Wu Q, Cao L. MiR-27b targets PI3K p110alpha to inhibit proliferation and migration in colorectal cancer stem cell. Am J Transl Res. 2019;11(9):5988–97.PubMedPubMedCentral
10.
11.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.PubMedCrossRef
12.
Ambros V, Chen X. The regulation of genes and genomes by small RNAs. Development. 2007;134(9):1635–41.PubMedCrossRef
13.
Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene. 2007;26(19):2799–803.PubMedCrossRef
14.
Kim NH, Cha YH, Kang SE, Lee Y, Lee I, Cha SY, Ryu JK, Na JM, Park C, Yoon HG, et al. p53 regulates nuclear GSK-3 levels through miR-34-mediated Axin2 suppression in colorectal cancer cells. Cell Cycle. 2013;12(10):1578–87.PubMedPubMedCentralCrossRef
15.
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102(39):13944–9.PubMedCrossRefPubMedCentral
16.
17.
18.
Sun S, Hang T, Zhang B, Zhu L, Wu Y, Lv X, Huang Q, Yao H. miRNA-708 functions as a tumor suppressor in colorectal cancer by targeting ZEB1 through Akt/mTOR signaling pathway. Am J Transl Res. 2019;11(9):5338–56.PubMedPubMedCentral
19.
He Z, Dang J, Song A, Cui X, Ma Z, Zhang Y. The involvement of miR-150/beta-catenin axis in colorectal cancer progression. Biomed Pharmacother. 2019;121:109495.PubMedCrossRef
20.
Wang W, He Y, Rui J, Xu MQ. miR-410 acts as an oncogene in colorectal cancer cells by targeting dickkopf-related protein 1 via the Wnt/beta-catenin signaling pathway. Oncol Lett. 2019;17(1):807–14.PubMed
21.
Ren D, Lin B, Zhang X, Peng Y, Ye Z, Ma Y, Liang Y, Cao L, Li X, Li R, et al. Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway. Oncotarget. 2017;8(30):49807–23.PubMedPubMedCentralCrossRef
22.
Unoki M, Kumamoto K, Takenoshita S, Harris CC. Reviewing the current classification of inhibitor of growth family proteins. Cancer Sci. 2009;100(7):1173–9.PubMedCrossRef
23.
Ullah M, Pelletier N, Xiao L, Zhao SP, Wang K, Degerny C, Tahmasebi S, Cayrou C, Doyon Y, Goh SL, et al. Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. Mol Cell Biol. 2008;28(22):6828–43.PubMedPubMedCentralCrossRef
24.
Doyon Y, Cayrou C, Ullah M, Landry AJ, Cote V, Selleck W, Lane WS, Tan S, Yang XJ, Cote J. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell. 2006;21(1):51–64.PubMedCrossRef
25.
Linzen U, Lilischkis R, Pandithage R, Schilling B, Ullius A, Luscher-Firzlaff J, Kremmer E, Luscher B, Vervoorts J. ING5 is phosphorylated by CDK2 and controls cell proliferation independently of p53. PLoS ONE. 2015;10(4):e0123736.PubMedPubMedCentralCrossRef
26.
Liu N, Wang J, Wang R, Liu Z, Yu Y, Lu H. ING5 is a Tip60 cofactor that acetylates p53 in response to DNA damage. Cancer Res. 2013;73(12):3749–60.PubMedCrossRef
27.
Gunduz M, Gunduz E, Rivera RS, Nagatsuka H. The inhibitor of growth (ING) gene family: potential role in cancer therapy. Curr Cancer Drug Targets. 2008;8(4):275–84.PubMedCrossRef
28.
OIE. Manual of diagnostic tests and vaccines for terrestrial animals. Paris: World Organisation for Animal Health; 2013. p. 1185–91.
29.
Aithal MG, Rajeswari N. Validation of housekeeping genes for gene expression analysis in glioblastoma using quantitative real-time polymerase chain reaction. Brain Tumor Res Treat. 2015;3(1):24–9.PubMedPubMedCentralCrossRef
30.
31.
Zhu X, Rao X, Yao W, Zou X. Downregulation of MiR-196b-5p impedes cell proliferation and metastasis in breast cancer through regulating COL1A1. Am J Transl Res. 2018;10(10):3122–32.PubMedPubMedCentral
32.
Xie J, Tan ZH, Tang X, Mo MS, Liu YP, Gan RL, Li Y, Zhang L, Li GQ. MiR-374b-5p suppresses RECK expression and promotes gastric cancer cell invasion and metastasis. World J Gastroenterol. 2014;20(46):17439–47.PubMedPubMedCentralCrossRef
33.
Liu J, Ma L, Wang Z, Wang L, Liu C, Chen R, Zhang J. MicroRNA expression profile of gastric cancer stem cells in the MKN-45 cancer cell line. Acta Biochim Biophys Sin. 2014;46(2):92–9.PubMedCrossRef
34.
Shao L, Chen Z, Peng D, Soutto M, Zhu S, Bates A, Zhang S, El-Rifai W. Methylation of the HOXA10 promoter directs miR-196b-5p-dependent cell proliferation and invasion of gastric cancer cells. MCR. 2018;16(4):696–706.PubMedCrossRef
35.
Zhang T, Meng J, Liu X, Zhang X, Peng X, Cheng Z, et al. ING5 differentially regulates protein lysine acetylation and promotes p300 autoacetylation. Oncotarget. 2018;9:1617–29.PubMedCrossRef
36.
Gao W, Han J. Overexpression of ING5 inhibits HGF-induced proliferation, invasion and EMT in thyroid cancer cells via regulation of the c-Met/PI3K/Akt signaling pathway. Biomed Pharmacother. 2018;98:265–70.PubMedCrossRef
37.
Gou WF, Shen DF, Yang XF, Zhao S, Liu YP, Sun HZ, Su RJ, Luo JS, Zheng HC. ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression. Oncotarget. 2015;6(23):19552–79.PubMedPubMedCentralCrossRef
38.
Zhao S, Yang XF, Shen DF, Gao Y, Shi S, Wu JC, Liu HX, Sun HZ, Su RJ, Zheng HC. The down-regulated ING5 expression in lung cancer: a potential target of gene therapy. Oncotarget. 2016;7(34):54596–615.PubMedPubMedCentralCrossRef
39.
Zhang Y, Tang C, Yu T, Zhang R, Zheng H, Yan W. MicroRNAs control mRNA fate by compartmentalization based on 3′ UTR length in male germ cells. Genome Biol. 2017;18(1):105.PubMedPubMedCentralCrossRef
40.
Kuwano Y, Nishida K, Kajita K, Satake Y, Akaike Y, Fujita K, Kano S, Masuda K, Rokutan K. Transformer 2beta and miR-204 regulate apoptosis through competitive binding to 3′ UTR of BCL2 mRNA. Cell Death Differ. 2015;22(5):815–25.PubMedCrossRef
41.
Chen WT, Yang YJ, Zhang ZD, An Q, Li N, Liu W, Yang B. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. J Ovar Res. 2017;10(1):1.CrossRef
42.
Ye P, Ke X, Zang X, Sun H, Dong Z, Lin J, Wang L, Liu W, Miao G, Tan Y, et al. Up-regulated MiR-27-3p promotes the G1-S phase transition by targeting inhibitor of growth family member 5 in osteosarcoma. Biomed Pharmacother. 2018;101:219–27.PubMedCrossRef
43.
Liu XL, Zhang XT, Meng J, Zhang HF, Zhao Y, Li C, Sun Y, Mei QB, Zhang F, Zhang T. ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways. Oncotarget. 2017;8(33):54265–76.PubMedPubMedCentralCrossRef
44.
45.
Yang W, Xiao W, Cai Z, Jin S, Li T. miR-1269b drives cisplatin resistance of human non-small cell lung cancer via modulating the PTEN/PI3K/AKT signaling pathway. OncoTargets Ther. 2020;13:109–18.CrossRef
46.
Pei L, Kong Y, Shao C, Yue X, Wang Z, Zhang N. Heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to pharmorubicin by promoting autophagy via PI3K/Akt pathway. J Cell Mol Med. 2018;22:5311–21.PubMedPubMedCentralCrossRef
47.
Li NA, Wang W, Xu B, Gong H. miR-196b regulates gastric cancer cell proliferation and invasion via PI3K/AKT/mTOR signaling pathway. Oncol Lett. 2016;11(3):1745–9.PubMedPubMedCentralCrossRef
Metadata
Title
MicroRNA-196b-5p promotes malignant progression of colorectal cancer by targeting ING5
Authors
He Xin
Chuanzhuo Wang
Yuan Chi
Zhaoyu Liu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01200-3

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Expression profile analysis identifies key genes as prognostic markers for metastasis of osteosarcoma

Primary research

Identification of key biomarkers associated with cell adhesion in multiple myeloma by integrated bioinformatics analysis

Primary research

Circ_0007841 promotes the progression of multiple myeloma through targeting miR-338-3p/BRD4 signaling cascade

Primary research

Network analysis of KLF5 targets showing the potential oncogenic role of SNHG12 in colorectal cancer

Primary research

Efficacy analysis of intraoperative radiotherapy in patients with early-stage breast cancer

Primary research

CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8+ T cells via NF-κB signaling
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits